Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
Breast Cancer|Lung Cancer|Hepatocellular Cancer|Colorectal Cancer|Pancreatic Cancer|Renal Cancer
DRUG: NIS793|DRUG: PDR001
Incidence of DLTs, AEs, SAEs and dose reductions / interruptions for NIS793, Up to 90 days after end of treatment|Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001, Up to 150 days after end of treatment
Best overall response (BOR), Evaluate the anti-tumor activity per RECIST as well as per immune related Response Criteria (irRC) of NIS793 as single agent and in combination with PDR001 every 2 cycles from start of treatment until cycle 9 then every 3 cycles until end of treatment (if applicable)., 48 months|Disease control rate (DCR), Evaluate the anti-tumor activity per RECIST as well as per immune related Response Criteria (irRC) of NIS793 as single agent and in combination with PDR001every 2 cycles from start of treatment until cycle 9 then every 3 cycles until end of treatment (if applicable)., 48 months|Overall response rate (ORR), Evaluate the anti-tumor activity per RECIST as well as per immune related Response Criteria (irRC) of NIS793 as single agent and in combination with PDR001 every2 cycles from start of treatment until cycle 9 then every 3 cycles until end of treatment (if applicable)., 48 months|Progression free survival (PFS), Evaluate the anti-tumor activity per RECIST as well as per immune related Response Criteria (irRC) of NIS793 as single agent and in combination with PDR001 every 2 cycles from start of treatment until cycle 9 then every 3 cycles until end of treatment. During disease progression f/u, every 8 weeks for 40 weeks, then every 12 weeks., 48 months|Duration of response (DOR), Evaluate the anti-tumor activity per RECIST as well as per immune related Response Criteria (irRC) of NIS793 as single agent and in combination with PDR001 every 2 cycles from start of treatment until cycle 9 then every 3 cycles until end of treatment (if applicable)., 48 months|Serum concentration-time profiles of NIS793 single agent and NIS793 in combination with PDR001, Evaluate serum concentration of NIS793 and PDR001 up to 8 cycles after start of treatment and at end of treatment., 48 months|Presence of anti-NIS793 and anti-PDR001 antibodies, Assess the emergence of anti-NIS793 and anti-PDR001 antibodies up to 8 cycles after start of treatment and at end of treatment., 48 months|Concentration of anti-NIS793 and anti-PDR001 antibodies, Assess the concentration of anti-NIS793 and anti-PDR001 antibodies up to 8 cycles after start of treatment and at end of treatment., 48 months|Area under the curve (AUC) for NIS793 single agent and NIS793 in combination with PDR001., Characterize the pharmacokinetic properties of NIS793 given alone and in combination with PDR001., 48 months|Cmax for NIS793 single agent and NIS793 in combination with PDR001., Characterize the pharmacokinetic properties of NIS793 given alone and in combination with PDR001., 48 months|Tmax for NIS793 single agent and NIS793 in combination with PDR001., Characterize the pharmacokinetic properties of NIS793 given alone and in combination with PDR001., 48 months|Half life of NIS793 as single agent and in combination with PDR001., Characterize the pharmacokinetic properties of NIS793 given alone and in combination with PDR001., 48 months|Characterization of tumor infiltrating lymphocytes (TILs) by H&E, Assess change from baseline of immune infiltrates in tumor biopsies after 2 cycles of treatment., 48 months|Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1, Assess change from baseline in immunological markers in tumor biopsies after 2 cycles of treatment., 48 months
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.